Please login to the form below
Indivior
The transatlantic opioid crisis
These worrying trends, official investigations in the UK, like The Gosport Inquiry in 2018, and allegations made against British pharma business, Indivior, create fertile ground for potential litigation on these shores.
As the opioid crisis grabs the headlines, the search for safe treatments continues
Indivior’s Gilles Picard charts a path to greater patient access and new therapies. ... It is hardly the easiest climate in which to market an opioid-based drug to treat addiction, while at the same time developing new treatments, but Indivior, the
Reckitt hammered by $1.4bn opioid settlement bill
The federal investigation centred on a former Reckitt pharmaceutical subsidiary – spun off in 2014 and renamed Indivior – and marketing practices it deployed for Suboxone between 2006 and 2015. ... Indivior is also in the firing line, and in April
Drug launches to watch in 2019
Compared with a similar treatment marketed by Indivior, the drug has advantages in flexibility.
Horizon Discovery and C4X to harness CRISPR for new cancer drugs
C4XD has already had success in this strategy, having signed an outlicensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
